Neuroendocrine tumors show altered expression of chondroitin sulfate, glypican 1, glypican 5, and syndecan 2 depending on their differentiation grade

Frontiers in Oncology

Volumn 4 FEB, Issue , 2014, Pages

  García Suárez, Olivia ^a   García, Beatriz ^a   Fernández Vega, Iván ^b   Astudillo, Aurora ^b,c   Quirós, Luis M ^a,c  

^a UNIVERSITY OF OVIEDO   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

Author keywords

Chondroitin sulfate; Glycosaminoglycan; Glypican 1; Glypican 5; Neuroendocrine tumor; Proteoglycan; Syndecan 2

Indexed keywords

AGRIN; BETA ACTIN; BETA N ACETYLGLUCOSAMINYLGLYCOPEPTIDE BETA 1, 4 GALACTOSYLTRANSFERASE; CHONDROITIN SULFATE; COLLAGEN TYPE 18; COMPLEMENTARY DNA; CORE PROTEIN; GLYPICAN 1; GLYPICAN 5; HEPARAN SULFATE; MONOCLONAL ANTIBODY; N ACETYLGALACTOSAMINE; N ACETYLGALACTOSAMINYLTRANSFERASE; PERLECAN; PROTEOGLYCAN; SULFOTRANSFERASE; SYNDECAN 2; UNCLASSIFIED DRUG; XYLOSE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ISOENZYME ANALYSIS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMOR; NEUROSECRETORY CELL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS REGULATION; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; TUMOR GROWTH; ULTRAVIOLET SPECTROPHOTOMETRY; VERY ELDERLY;

EID: 84899086827     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00015     Document Type: Article

References (59)

1. Warner RR. Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology (2008) 128:1668-84. doi:10.1053/j.gastro.2005.03.078
2. Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology (2004) 80:3-7. doi:10.1159/000080731
3. Duerr EM, Chung DC. Molecular genetics of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab (2007) 21:1-14. doi:10.1016/j.beem.2006.12.001
4. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors. Pancreas (2010) 39:707-12. doi:10.1097/MPA.0b013e3181ec124e
5. Shia J, Tang LH, Weiser MR, Brenner B, Adsay NV, Stelow EB, et al. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol (2008) 32:719-31. doi:10.1097/PAS.0b013e318159371c
6. Maitra A, Hansel DE, Argani P, Ashfaq R, Rahman A, Naji A, et al. Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. Clin Cancer Res (2003) 9:5988-95. doi:10.1186/1476-4598-7-11
7. Bloomston M, Durkin A, Yang I, Rojiani M, Rosemurgy AS, Enkmann S, et al. Identification of molecular markers specific for pancreatic neuroendocrine tumors by genetic profiling of core biopsies. Ann Surg Oncol (2004) 11:413-9. doi:10.1245/ASO.2004.03.077
8. Dilley WG, Kalyanaraman S, Verma S, Cobb JP, Laramie JM, Lairmore TC. Global gene expression in neuroendocrine tumors from patients with the MEN1 syndrome. Mol Cancer (2005) 4:9. doi:10.1186/1476-4598-4-9
9. Capurso G, Lattimore S, Crnogorac-Jurcevic T, Panzuto F, Milione M, Bhakta V, et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr Relat Cancer (2006) 13:541-58. doi:10.1677/erc.1.01153
10. Whitelock JM, Iozzo R. Heparan sulfate: a complex polymer charged with biological activity. Chem Rev (2005) 105:2745-64. doi:10.1021/cr010213m
11. Esko JD, Selleck S. Order out of chaos: assembly of ligand binding sites in heparan sulphate. Annu Rev Biochem (2002) 71:435-71. doi:10.1146/annurev.biochem.71.110601.135458
12. Afratis N, Gialeli C, Nikitovic D, Tsegenidis T, Karousou E, Theocharis AD, et al. Glycosaminoglycans: key players in cancer cell biology and treatment. FEBS J (2012) 279:1177-97. doi:10.1111/j.1742-4658.2012.08529.x
13. Lindahl U, Kjellén L. Pathophysiology of heparan sulphate: many diseases, few drugs. J Intern Med (2013) 273:555-71. doi:10.1111/joim.12061
14. Iozzo RV, Sanderson RD. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med (2011) 15:1013-31. doi:10.1111/j.1582-4934.2010.01236.x
15. Wade A, Robinson AE, Engler JR, Petritsch C, James CD, Philips JJ. Proteoglycans and their roles in brain cancer. FEBS J (2013) 280:2399-417. doi:10.1111/febs.12109
16. García-Suárez O, Fernández-Vega I, Quirós LM. Multiple alterations of heparan sulphate in cancer. OA Cancer (2013) 1(1):1.
17. Parish CR. The role of heparan sulphate in inflammation. Nat Rev Immunol (2006) 6:633-43. doi:10.1038/nri1918
18. Shinji S, Tajiri T, Ishiwata T, Seya T, Tanaka N, Naito Z. Different expression levels of lumican in human carcinoid tumor and neuroendocrine cell carcinoma. Int J Oncol (2005) 26:873-80. doi:10.1016/j.yexmp.2010.01.010
19. Hunter KE, Palermo C, Kester JC, Simpson K, Li JP, Tang LH, et al. Heparanase promotes lymphangiogenesis and tumor invasion in pancreatic neuroendocrine tumors. Oncogene (2013). doi:10.1038/onc.2013.142
20. Schefe JH, Lehmann KE, Buschmann IR, Unger T, Funke-Kaiser H. Quantitative real-time RT-PCR data analysis: current concepts and the novel "gene expression's CT difference" formula. J Mol Med (2006) 84:901-10. doi:10.1007/s00109-006-0097-6
21. Iozzo RV. Heparan sulfate proteoglycans: intricate molecules with intriguing functions. J Clin Invest (2002) 108:165-7. doi:10.1172/JCI13560
22. Mougey AM, Adler DC. Neuroendocrine tumors: review and clinical update. Hosp Physician (2007) 51:12-20.
23. Nairn AV, Kinoshita-Toyoda A, Toyoda H, Xie J, Harris K, Dalton S, et al. Glycomics of proteoglycan biosynthesis in murine embryonic stem cell differentiation. J Proteome Res (2007) 6:4374-87. doi:10.1021/pr070446f
24. Nadanaka S, Zhou S, Kagiyama S, Shoji N, Sugahara K, Sugihara K, et al. EXTL2, a member of EXT family of tumor suppressor, controls glycosaminoglycan biosynthesis in a xylose kinase-dependent manner. J Biol Chem (2013) 288:9321-33. doi:10.1074/jbc.M112.416909
25. Esko JD, Lindahl U. Molecular diversity of heparan sulphate. J Clin Invest (2001) 108:169-73. doi:10.1172/JCI13530
26. Xinnong J, Couchman J. Perlecan and tumor angiogenesis. J Histochem Cytochem (2003) 51:1393-410. doi:10.1177/002215540305101101
27. Fernández-Vega I, García O, Crespo A, Castañón S, Menéndez P, Astudillo A, et al. Specific genes involved in synthesis and editing of heparan sulfate proteoglycans show altered expression patterns in breast cancer. BMC Cancer (2013) 13:24. doi:10.1186/1471-2407-13-24
28. Kwon MJ, Jang B, Yi JY, Han IO, Oh ES. Syndecans play dual roles as cell adhesion receptors and docking receptors. FEBS Lett (2012) 586:2207-11. doi:10.1016/j.febslet.2012.05.037
29. Park H, Kim Y, Lim Y, Han I, Oh ES. Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells. J Biol Chem (2002) 277:29730-6. doi:10.1074/jbc.M202435200
30. Munesue S, Kusano Y, Oguri K, Itano N, Yoshitomi Y, Nakanishi H, et al. The role of syndecan-2 in regulation of actin-cytoskeletal organization of Lewis lung carcinoma-derived metastatic clones. Biochem J (2002) 363:201-9. doi:10.1042/0264-6021:3630201
31. Fears CY, Gladson CL, Woods A. Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells. J Biol Chem (2006) 281:14533-6. doi:10.1074/jbc.C600075200
32. Fears CY, Woods A. The role of syndecans in disease and wound healing. Matrix Biol (2006) 25:443-56. doi:10.1016/j.matbio.2006.07.003
33. Theocharis AD, Skandalis SS, Tzanakakis GN, Karamanos NK. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J (2010) 277:3904-23. doi:10.1111/j.1742-4658.2010.07800.x
34. Chen E, Hermanson S, Ekker S. Syndecan-2 is essential for angiogenic sprouting during zebrafish development. Blood (2004) 103:1710-9. doi:10.1182/blood-2003-06-1783
35. Noguer O, Villena J, Lorita J, Vilaró S, Reina M. Syndecan-2 downregulation impairs angiogenesis in human microvascular endotelial cells. Exp Cell Res (2009) 315:795-808. doi:10.1016/j.yexcr.2008.11.016
36. Huang X, Xiao DW, Xu LY, Zhong HJ, Liao LD, Xie ZF, et al. Prognostic significance of altered expression of SDC2 and CYR61 in esophageal squamous cell carcinoma. Oncol Rep (2009) 21:1123-9. doi:10.3892/or_00000332
37. Popovic A, Demirovic A, Spajic B, Stimac G, Kruslin B, Tomas D. Expression and prognostic role of syndecan-2 in prostate cancer. Prostate Cancer Prostatic Dis (2009) 13:78-82. doi:10.1038/pcan.2009.43
38. Hrabar D, Aralica G, Gomercic M, Ljubicic N, Kruslin B, Tomas D. Epithelial and stromal expression of syndecan-2 in pancreatic carcinoma. Anticancer Res (2010) 30:2749-53.
39. Munesue S, Yoshitomi Y, Kusano Y, Koyama Y, Nishiyama A, Nakanishi H, et al. A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J Biol Chem (2007) 282:28164-74. doi:10.1074/jbc.M609812200
40. Modrowski D, Orosco A, Thévenard J, Fromigué O, Marie PJ. Syndecan-2 overexpression induces osteosarcoma cell apoptosis: implication of syndecan-2 cytoplasmic domain and JNK signaling. Bone (2005) 37:180-9. doi:10.1016/j.bone.2005.04.010
41. Filmus J, Capurro M, Rast J. Glypicans. Genome Biol (2008) 9:224. doi:10.1186/gb-2008-9-5-224
42. Maier T, Güell M, Serrano L. Correlation of mRNA and protein in complex biological samples. FEBS Lett (2009) 583:3966-73. doi:10.1016/j.febslet.2009.10.036
43. Chen G, Gharib TG, Huang CC, Taylor JM, Misek DE, Kardia SL, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics (2002) 1:304-13. doi:10.1074/mcp.M200008-MCP200
44. Ørntoft TF, Thykjaer T, Waldman FM, Wolf H, Celis JE. Genome-wide study of gene copy numbers, transcripts, and protein levels in pairs of non-invasive and invasive human transitional cell carcinomas. Mol Cell Proteomics (2002) 1:37-45. doi:10.1074/mcp.M100019-MCP200
45. Yu W, Inoue J, Imoto I, Matsuo Y, Karpas A, Inazawa J. GPC5 is a possible target for the 13q31-q32 amplification detected in lymphoma cell lines. J Hum Genet (2003) 48:331-5. doi:10.1007/s10038-003-0026-2
46. Williamson D, Selfe J, Gordon T, Lu YJ, Pritchard-Jones K, Murai K, et al. Role for amplification and expression of glypican-5 in rhabdomyosarcoma. Cancer Res (2007) 67:57-65. doi:10.1158/0008-5472.CAN-06-1650
47. Yeaman C, Rapraeger AC. Post-transcriptional regulation of syndecan-1 expression by cAMP in peritoneal macrophages. J Cell Biol (1993) 122:941-50. doi:10.1083/jcb.122.4.941
48. Grobe K, Esko JD. Regulated translation of heparan sulfate N-acetylglucosamine N-deacetylase/n-sulfotransferase isozymes by structured 5'-untranslated regions and internal ribosome entry sites. J Biol Chem (2002) 277:30699-706. doi:10.1074/jbc.M111904200
49. Arvatz G, Barash U, Nativ O, Ilan N, Vlodavsky I. Post-transcriptional regulation of heparanase gene expression by a 3' AU-rich element. FASEB J (2010) 24:4969-76. doi:10.1096/fj.10-156372
50. Su G, Meyer K, Nandini CD, Qiao D, Salamat S, Friedl A. Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells. Am J Pathol (2006) 168:2014-26. doi:10.2353/ajpath.2006.050800
51. Kleeff J, Ishiwata T, Kumbasar A, Friess H, Büchler MW, Lander AD, et al. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest (1998) 102:1662-73. doi:10.1172/JCI4105
52. Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, et al. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res (2001) 61:5562-9.
53. Suhovskih AV, Mostovich LA, Kunin IS, Boboev MM, Nepomnyashchikh GI, Aidagulova SV, et al. Proteoglycan expression in normal human prostate tissue and prostate cancer. ISRN Oncol (2013) 2013:680136. doi:10.1155/2013/680136
54. Fico A, Maina F, Dono R. Fine-tuning of cell signalling by glypicans. Cell Mol Life Sci (2011) 68:923-9. doi:10.1007/s00018-007-7471-6
55. Jia HL, Ye QH, Qin LX, Budhu A, Forgues M, Chen Y, et al. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res (2007) 13:1133-9. doi:10.1158/1078-0432.CCR-06-1025
56. Iida J, Meijne AM, Knutson JR, Furcht LT, McCarthy JB. Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion. Semin Cancer Biol (1996) 7:155-62. doi:10.1006/scbi.1996.0021
57. Ito Y, Hikino M, Yajima Y, Mikami T, Sirko S, von Holst A, et al. Structural characterization of the epitopes of the monoclonal antibodies 473HD, CS-56, and MO-225 specific for chondroitin sulfate D-type using the oligosaccharide library. Glycobiology (2005) 15:593-603. doi:10.1093/glycob/cwi036
58. Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR, et al. Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. Clin Cancer Res (1997) 3:983-92.
59. Prinz RD, Willis CM, Viloria-Petit A, Klüppel M. Elimination of breast tumor-associated chondroitin sulfate promotes metastasis. Genet Mol Res (2011) 10:3901-13. doi:10.4238/2011.December.8.9